Last €38.74 EUR
Change Today +1.23 / 3.28%
Volume 811.5K
GRF On Other Exchanges
Symbol
Exchange
OTC US
OTC US
NASDAQ GS
OTC US
Continuous
Continuous
Frankfurt
Frankfurt
As of 11:38 AM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

grifols sa (GRF) Snapshot

Open
€37.79
Previous Close
€37.51
Day High
€38.80
Day Low
€37.63
52 Week High
06/10/14 - €42.53
52 Week Low
10/23/13 - €28.25
Market Cap
12.3B
Average Volume 10 Days
673.7K
EPS TTM
€1.09
Shares Outstanding
213.1M
EX-Date
06/5/14
P/E TM
35.6x
Dividend
€0.20
Dividend Yield
0.52%
Current Stock Chart for GRIFOLS SA (GRF)

Related News

No related news articles were found.

grifols sa (GRF) Related Businessweek News

No Related Businessweek News Found

grifols sa (GRF) Details

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, Canada, and internationally. It specializes in providing infusion solutions, nutrition products, medical devices, and diagnostic instrumentation and reagents for use in hospitals and clinics. The company operates through four divisions: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience division manufactures and sells plasma derivatives for therapeutic use, such as the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This division offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic division focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments and reagents for diagnostics, as well as blood bank products. This division primarily serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital division manufactures and installs products used by and in hospitals, including parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others division is involved in the sale of intermediate pastes and plasma products, as well as provision of engineering services to external companies. The company’s products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and a range of other medical conditions. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

13,200 Employees
Last Reported Date: 05/6/14
Founded in 1940

grifols sa (GRF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

grifols sa (GRF) Key Developments

Grifols Celebrates Opening of New North Fractionation Facility in Clayton, NC

Grifols celebrated the opening of its new North Fractionation Facility (NFF) in Clayton, NC, where production capacity of plasma will almost double to approximately 6 million liters annually. Grifols' products are used to treat rare, chronic diseases such as a neurological disorder, immune deficiencies, hemophilia and genetic emphysema. NFF will be fully operational in 2015 with over 200 employees. The 155,000 square-foot facility features technologically advanced systems and processes to ensure the standards of product quality and high production capacity in plasma fractionation. Fractionation is the first step in the production of plasma-derived therapies, which involves subjecting plasma to various changes of temperature and chemical conditions, causing each of the proteins with therapeutic properties to separate out. These proteins have to be purified and formulated before they can be used as medicines. The medicines manufactured by Grifols from plasma include immunoglobulin, for the treatment of primary immune deficiency and a neurological disorder called chronic inflammatory demyelinating polyneuropathy (CIDP), factor VIII, for the treatment of hemophilia A, albumin, to re-establish and maintain blood volume and alpha-1 antitrypsin for the treatment of genetic emphysema. The $370 million invested in NFF at its Clayton facility is included in the Capital Investment Plan (CAPEX) for the period 2012-2014. In addition, organic growth continues and new investments are planned to expand and increase Grifols' production facilities in both Spain and the United States. Grifols plans to allocate approximately EUR 600 million to capital expenditures between 2014 and 2016.

Grifols, S.A. - Shareholder/Analyst Call

Grifols, S.A. - Shareholder/Analyst Call

Grifols, S.A. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014

Grifols, S.A. reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. Revenues grew year on year (y/y) by 16.7% to EUR 798 million (USD 1.111 billion), boosted by the January 2014 acquisition of Novartis (Switzerland)'s diagnostic unit. Accounting for 75.3% of Grifols' total revenue in the first-quarter, sales of its Bioscience division amounted to EUR 601 million (a drop of 0.6%). This was driven by the performance of the firm's key plasma proteins, including an alpha-1 antitrypsin. In the first quarter, EBITDA rose by 31.9% to reach EUR 270 million. Profit before tax was EUR 155,370,000 compared to EUR 125,288,000 a year ago. Profit after income tax from continuing operations was EUR 119,635,000 compared to EUR 89,547,000 a year ago. Profit attributable to equity holders of the parent was EUR 120,973,000 compared to EUR 91,002,000 a year ago. Basic and diluted earnings per share was EUR 0.35 compared to EUR 0.27 a year ago. Net cash from operating activities was EUR 124,867,000 compared to EUR 92,378,000 a year ago. Property, plant and equipment and intangible assets were EUR 50,322,000 compared to EUR 32,440,000 a year ago. Property, plant and equipment were EUR 42,335,000 compared to EUR 27,522,000 a year ago. Intangible assets were EUR 7,987,000 compared to EUR 4,918,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GRF:SM €38.74 EUR +1.23

GRF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $69.57 USD +0.93
Hikma Pharmaceuticals PLC 1,787 GBp +76.00
Hospira Inc $50.78 USD +0.31
Stada Arzneimittel AG €31.78 EUR -0.68
UCB SA €65.51 EUR +1.54
View Industry Companies
 

Industry Analysis

GRF

Industry Average

Valuation GRF Industry Range
Price/Earnings 33.8x
Price/Sales 4.5x
Price/Book 5.7x
Price/Cash Flow 20.9x
TEV/Sales 1.2x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GRIFOLS SA, please visit www.grifols.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.